Deutsche Bank Starts Teva Pharma (TEVA) at Buy
- Top 10 News for 4/25 - 4/29: Merger Madness!; Valeant Hies New Boss; Icahn's Exit of Apple Could be Telling Sign
- Wall Street falls as earnings weigh; Dow, S&P up for month
- Amazon.com (AMZN) Tops Q1 EPS by 49c; Issues Q2 Outlook
- Exclusive: Yahoo's bidder shortlist points to cash deal -sources
- Yen posts biggest weekly gain since 2008, stocks slip
Deutsche Bank initiated coverage on Teva Pharma (NYSE: TEVA) with a Buy rating and a price target of $63.00.
Analyst Gregg Gilbert said, "While the potential cliff for Copaxone looms and the generics business has not been without challenges, we like the combination of valuation, attractive dividend yield (similar to Big Pharma), and the potential for greater focus on strategic initiatives that increase shareholder value under new CEO Erez Vigodman. We see the recent hire of industry veteran Siggi Olafsson to run global generics and the simplification of the management structure as positive steps, and we sense that investors are skeptical about cost savings initiatives, the entire branded product pipeline, and Teva’s ability/desire to do deals."
Shares of Teva Pharma closed at $54.95 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FBR Capital Downgrades Cloud Peak Energy (CLD) to Underperform
- Seagate (STX) PT Cut to $25 at Baird
- Qlik Technologies (QLIK) PT Raised to $40 at UBS
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, New Coverage
Related EntitiesDeutsche Bank, Dividend
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!